Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
Geron (GERN) Stock Price & Analysis
1,930 Followers
GERN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.64 - $4.30
Previous Close$3.55
Volume6.13M
Average Volume (3M)12.75M
Market Cap
$2.19B
Enterprise Value$1.86B
Total Cash (Recent Filing)$333.70M
Total Debt (Recent Filing)$85.90M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 01, 2024EPS Estimate
-$0.1Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding593,132,540
10 Day Avg. Volume7,651,340
30 Day Avg. Volume12,752,235
Standard Deviation0.18
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)8.49
Price to Sales (P/S)91548.71
Price to Cash Flow (P/CF)-12.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.84K
Enterprise Value/Gross Profit7.84K
Enterprise Value/Ebitda-10.19
Forecast
1Y Price Target
$6.08Price Target Upside64.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Geron News
Bulls Say, Bears Say
Bulls Say
Commercial StrategyGeron Corporation is positioning to launch imetelstat on its own upon potential approval with a fully onboarded commercial team.
Market PotentialAnalyst expects high demand and models $3.3B in global sales by 2035 for imetelstat.
Regulatory MilestoneImetelstat has nearly a 100% probability of approval after a favorable FDA AdCom vote.
Bears Say
Financial PressureThe company's cash runway guidance has been shortened, indicating potential financial pressure.
Regulatory ConcernsFDA reviewers maintained a fairly strongly negative tone throughout the discussion, potentially impacting the approval process.
Trial DelaysThe phase 3 ImpactMF trial readout has been delayed by over 6 months, reducing confidence in its success.
---
Ownership Overview
1.68% Insiders
8.86% Mutual Funds
53.77% Other Institutional Investors
35.69% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.64 and its highest was $4.30 in the past 12 months.
What is Geron Corp’s market cap?
Currently, no data Available
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Aug 01, 2024 which is in 59 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on May 02, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.096 by $0.006.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.15 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -$0.1.
How many shares outstanding does Geron Corp have?
Geron Corp has 593,132,570 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.096. Following the earnings report the stock price went down -3.186%.
Which hedge fund is a major shareholder of Geron Corp?
Among the largest hedge funds holding Geron Corp’s share is RA Capital Management. It holds Geron Corp’s shares valued at 152M.
---
Geron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.08 (64.32% Upside)
$6.08 (64.32% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 16.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.56%
12-Months-Change
Fundamentals
Return on Equity
-60.04%
Trailing 12-Months
Asset Growth
13.46%
Trailing 12-Months
Company Description
Geron Corp
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
---
GERN Company Deck
---
GERN Earnings Call
Q1 2024
0:00 / 0:00
---
GERN Stock 12 Month Forecast
Average Price Target
$6.08
▲(64.32% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Arrowhead Pharmaceuticals
―
Kura Oncology
―
Protagonist Therapeutics
―
Best Analysts Covering GERN
1 Year
1 Year Success Rate
14/19 ratings generated profit
1 Year Average Return
+37.58%
reiterated a buy rating 3 months ago
Copying Kalpit Patel's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +37.58% per trade.
---